ClinicalTrials.gov
public full text
Public Domain
A Study Investigating the Efficacy and Safety of Ociperlimab and Tislelizumab and BAT1706 Combinations in Patients With Advanced HCC
This was a Phase 2, randomized, multicenter, open-label, 2-arm study to investigate the efficacy and safety of ociperlimab in combination with tislelizumab plus BAT1706, and tislelizumab plus BAT1706, as first-line treatment in participants with advanced Hepatocellular Carcinoma (HCC).
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Lenvatinib, Sintilimab Plus SIRT for Unresectable HCC#1446366
- Etoposide, Oxaliplatin and Capecitabine in Advanced Hepatocellular Carcinoma (HCC)#1351398
- A Study of Apatinib in Patients With Advanced Hepatocellular Carcinoma#1437567
- Hepatic Artery Infusion With Oxaliplatin#890061
- A Study of GC33 (RO5137382) in Patients With Advanced or Metastatic Hepatocellular Carcinoma#870110
Record · ID 1475843
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive